Atherosclerosis
Volume 205, Issue 1 , Pages 23-32 , July 2009

Cigarette smoking: An undertreated risk factor for cardiovascular disease

Received 24 October 2008 ,Revised 7 January 2009 ,Accepted 8 January 2009.

References 

  1. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics. Available at: http://www.heartstats.org [accessed June 18, 2008].
  2. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol. 2006;111:189–194
  3. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005;116:963–971
  4. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation. 2005;112:489–497
  5. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–852
  6. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control. 2004;13:388–395
  7. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity losses United States, 1997–2001. MMWR Morb Mortal Wkly Rep 2005;54:625–8.
  8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442
  9. WHO Tobacco Free Initiative . Building blocks for tobacco control: a handbook. Geneva, Switzerland: World Health Organization; 2004;
  10. Centers for Disease Control and Prevention. Cigarette smoking among adults United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:1157–61.
  11. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  12. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  13. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  14. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003
  15. Mähönen MS, McElduff P, Dobson AJ, Kuulasmaa KA, Evans AE. Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA Project populations. Tob Control. 2004;13:244–250
  16. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146
  17. Edwards R. The problem of tobacco smoking. BMJ. 2004;328:217–219
  18. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315:973–980
  19. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328:1519
  20. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647–658
  21. Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gen Med. 2006;3:279–291
  22. Heidrich J, Wellmann J, Heuschmann PU, Kraywinkel K, Keil U. Mortality and morbidity from coronary heart disease attributable to passive smoking. Eur Heart J. 2007;28:2498–2502
  23. Heuschmann PU, Heidrich J, Wellmann J, Kraywinkel K, Keil U. Stroke mortality and morbidity attributable to passive smoking in Germany. Eur J Cardiovasc Prev Rehabil. 2007;14:793–795
  24. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation. 2001;104:1905–1910
  25. Li H, Srinivasan SR, Chen W, Xu JH, Li S, Berenson GS. Vascular abnormalities in asymptomatic, healthy young adult smokers without other major cardiovascular risk factors: the Bogalusa Heart Study. Am J Hypertens. 2005;18:319–324
  26. Pittilo M. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 2000;81:219–230
  27. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131:1557–1566
  28. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989;298:784–788
  29. McGill HC. The cardiovascular pathology of smoking. Am Heart J. 1988;115:250–257
  30. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on endothelins and endothelial factors of the European society of hypertension. J Hypertens. 2005;23:233–246
  31. Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci (Lond). 2001;100:459–465
  32. Carty CS, Soloway PD, Kayastha S, et al. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg. 1996;24:927–934[discussion 34–5]
  33. Knight-Lozano CA, Young CG, Burow DL, et al. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105:849–854
  34. Funabashi N, Asano M, Komuro I. Predictors of non-calcified plaques in the coronary arteries of 242 subjects using multislice computed tomography and logistic regression models. Int J Cardiol. 2007;117:191–197
  35. Mahmud A, Feely J. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension. 2003;41:183–187
  36. Stefanadis C, Tsiamis E, Vlachopoulos C, et al. Unfavorable effect of smoking on the elastic properties of the human aorta. Circulation. 1997;95:31–38
  37. Fagerberg B, Bokemark L, Hulthe J. The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically healthy men. Nutr Metab Cardiovasc Dis. 2001;11:227–235
  38. Linna MS, Ahotupa M, Irjala K, et al. Smoking and low serum testosterone associates with high concentration of oxidized LDL. Ann Med. 2008;1–7
  39. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649–1654
  40. Folts JD, Bonebrake FC. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: inhibition with phentolamine. Circulation. 1982;65:465–470
  41. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6–14
  42. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999;180:S357–S363
  43. Gvozdjăk J, Gvozdjáková A, Kucharská J, Bada V. The effect of smoking on myocardial metabolism. Czech Med. 1987;10:47–53
  44. American Diabetes Association . Standards of medical care in diabetes 2006. Diabetes Care. 2006;29(Suppl. 1):S4–S42
  45. Haustein KO, Krause J, Haustein H, Rasmussen T, Cort N. Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). Int J Clin Pharmacol Ther. 2004;42:83–92
  46. Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med. 1994;97:242–249
  47. Botella-Carretero JI, Escobar-Morreale HF, Martín I, et al. Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm Metab Res. 2004;36:178–182
  48. Hatsukami DK, Kotlyar M, Allen S, et al. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest. 2005;128:2528–2537
  49. Eliasson B, Hjalmarson A, Kruse E, Landfeldt B, Westin A. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res. 2001;3:249–255
  50. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med. 2005;2:e160
  51. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86–97
  52. van Domburg RT, Meeter K, van Berkel DF, Veldkamp RF, van Herwerden LA, Bogers AJ. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36:878–883
  53. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000;160:939–944
  54. Centers for Disease Control and Prevention. Cigarette smoking among adults United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:642–5.
  55. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000;18:305–311
  56. Kreuter MW, Chheda SG, Bull FC. How does physician advice influence patient behavior? Evidence for a priming effect. Arch Fam Med. 2000;9:426–433
  57. Solberg LI, Asche SE, Boyle RG, Boucher JL, Pronk NP. Frequency of physician-directed assistance for smoking cessation in patients receiving cessation medications. Arch Intern Med. 2005;165:656–660
  58. Van Spall HG, Chong A, Tu JV. Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction. Am Heart J. 2007;154:213–220
  59. Wilson A, Sinfield P, Rodgers S, Hammersley V, Coleman T. Drugs to support smoking cessation in UK general practice: are evidence based guidelines being followed?. Qual Saf Health Care. 2006;15:284–288
  60. Shiffman S, Ferguson SG, Hellebusch SJ. Physicians’ counseling of patients when prescribing nicotine replacement therapy. Addict Behav. 2007;32:728–739
  61. Goldstein MG, DePue JD, Monroe AD, et al. A population-based survey of physician smoking cessation counseling practices. Prev Med. 1998;27:720–729
  62. Pipe A, Sorensen M, Reid R. Physician smoking status, attitudes toward smoking, and cessation advice to patients: an international survey. Patient Educ Couns. 2008;
  63. Kotz D, Wagena EJ, Wesseling G. Smoking cessation practices of Dutch general practitioners, cardiologists, and lung physicians. Respir Med. 2007;101:568–573
  64. Fiore M, Jaén C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008;
  65. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146
  66. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149:565–572
  67. Haustein KO. What can we do in secondary prevention of cigarette smoking?. Eur J Cardiovasc Prev Rehabil. 2003;10:476–485
  68. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–1431
  69. Hubbard R, Lewis S, Smith C, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control. 2005;14:416–421
  70. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281–299
  71. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946–955
  72. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006;119:1080–1087
  73. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003;59:767–773
  74. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;CD000031
  75. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477
  76. Pfizer. Effectiveness and safety of varenicline in smokers with cardiovascular disease who wish to quit smoking. Available at: http://clinicaltrials.gov/ct2/show/NCT00282984?term=Varenicline+AND+cardiovascular+disease&rank=1 [accessed October 24, 2008].
  77. Nides M, Glover E, Reus V, et al. Varenicline versus bupropion for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32:664–675
  78. Pfizer Inc. Chantix® (varenicline) tablets U.S. prescribing information. Available at: http://media.pfizer.com/files/products/uspi_chantix.pdf [accessed June 27, 2008].
  79. France EK, Glasgow RE, Marcus AC. Smoking cessation interventions among hospitalized patients: what have we learned?. Prev Med. 2001;32:376–388
  80. van Berkel TF, Boersma H, Roos-Hesselink JW, Erdman RA, Simoons ML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J. 1999;20:1773–1782
  81. Hilleman DE, Mohiuddin SM, Packard KA. Comparison of conservative and aggressive smoking cessation treatment strategies following coronary artery bypass graft surgery. Chest. 2004;125:435–438
  82. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2007;CD001837
  83. Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev. 2008;CD006886
  84. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446–452
  85. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care. 2007;23:71–79
  86. Quist-Paulsen P, Lydersen S, Bakke PS, Gallefoss F. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2006;13:274–280
  87. Pinget C, Martin E, Wasserfallen JB, Humair JP, Cornuz J. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling. Eur J Cardiovasc Prev Rehabil. 2007;14:451–455
  88. Ma J, Hampl JS, Betts NM. Antioxidant intakes and smoking status: data from the continuing survey of food intakes by individuals 1994–1996. Am J Clin Nutr. 2000;71:774–780
  89. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. J Am Coll Cardiol. 1992;20:287–294
  90. Pierce JP, Leon ME, on behalf of the IARC Handbook volume 13 Working Group and IARC Secretariat. Special report: policy. Effectiveness of smoke-free policies. Lancet Oncol 2008;9:614–5.
  91. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology. 2003;54:507–530
  92. Journath G, Nilsson PM, Petersson U, Paradis BA, Theobald H, Erhardt L. Hypertensive smokers have a worse cardiovascular risk profile than non-smokers in spite of treatment–a national study in Sweden. Blood Press. 2005;14:144–150
  93. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. 1997;336:755–761
  94. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol. 2002;55:654–664
  95. Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?. Circulation. 2001;104:773–778
  96. Law MR, Morris JK, Watt HC, Wald NJ. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br J Cancer. 1997;75:1690–1693

PII: S0021-9150(09)00014-8

doi: 10.1016/j.atherosclerosis.2009.01.007

Atherosclerosis
Volume 205, Issue 1 , Pages 23-32 , July 2009

Article Tools

* Image Usage & Resolution